BACKGROUND: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. PROCEDURE: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle. RESULTS: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. CONCLUSIONS: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease.
BACKGROUND: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. PROCEDURE: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle. RESULTS: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. CONCLUSIONS: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease.
Authors: A Cangir; T J Vietti; E A Gehan; E O Burgert; P Thomas; M Tefft; M E Nesbit; J Kissane; D Pritchard Journal: Cancer Date: 1990-09-01 Impact factor: 6.860
Authors: M Paulussen; S Ahrens; S Burdach; A Craft; B Dockhorn-Dworniczak; J Dunst; B Fröhlich; W Winkelmann; A Zoubek; H Jürgens Journal: Ann Oncol Date: 1998-03 Impact factor: 32.976
Authors: Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245
Authors: E Anders Kolb; Brian H Kushner; Richard Gorlick; Caroline Laverdiere; John H Healey; Michael P LaQuaglia; Andrew G Huvos; Jing Qin; Ha Thanh Vu; Leonard Wexler; Suzanne Wolden; Paul A Meyers Journal: J Clin Oncol Date: 2003-09-15 Impact factor: 44.544
Authors: B H Kushner; P A Meyers; W L Gerald; J H Healey; M P La Quaglia; P Boland; N Wollner; E S Casper; A Aledo; G Heller Journal: J Clin Oncol Date: 1995-11 Impact factor: 44.544
Authors: Carlos Rodríguez-Galindo; Tiebin Liu; Matthew J Krasin; Jianrong Wu; Catherine A Billups; Najat C Daw; Sheri L Spunt; Bhaskar N Rao; Victor M Santana; Fariba Navid Journal: Cancer Date: 2007-07-15 Impact factor: 6.860
Authors: James S Miser; Robert E Goldsby; Zhengjia Chen; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila G Moore; Aaron R Rausen; Teresa J Vietti; Holcombe E Grier Journal: Pediatr Blood Cancer Date: 2007-12 Impact factor: 3.167
Authors: Ya Zhang; Jingqing Yang; Na Zhao; Cao Wang; Santosh Kamar; Yonghong Zhou; Zewei He; Jifei Yang; Bin Sun; Xiaoqian Shi; Lei Han; Zuozhang Yang Journal: Oncol Lett Date: 2018-09-12 Impact factor: 2.967
Authors: Melissa D Mathias; Srikanth R Ambati; Alexander J Chou; Emily K Slotkin; Leonard H Wexler; Paul A Meyers; Heather Magnan Journal: Pediatr Blood Cancer Date: 2016-07-18 Impact factor: 3.167
Authors: Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening Journal: Cochrane Database Syst Rev Date: 2019-03-11
Authors: Kelly Bailey; Carrye Cost; Stephen Lessnick; Steven DuBois; Pooja Hingorani; Ian Davis; Julia Glade-Bender; Patrick Grohar; Peter Houghton; Michael Isakoff; Elizabeth Stewart; Nadia Laack; Jason Yustein; Damon Reed; Katherine Janeway; Richard Gorlick Journal: F1000Res Date: 2019-04-15
Authors: S Ventura; D N T Aryee; F Felicetti; A De Feo; C Mancarella; M C Manara; P Picci; M P Colombo; H Kovar; A Carè; K Scotlandi Journal: Oncogene Date: 2015-11-30 Impact factor: 9.867